vimarsana.com
Home
Live Updates
Accutar Biotechnology Presents Phase 1 Data of AC699 Monothe
Accutar Biotechnology Presents Phase 1 Data of AC699 Monothe
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
CRANBURY, N.J.--(BUSINESS WIRE)--Jun 1, 2024--
Related Keywords
United States ,
Chicago ,
Illinois ,
American ,
Jiaqi Ren ,
Accutar Biotechnology Inc ,
American Society Of Clinical Oncology ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
Developmental Therapeutics ,
Molecularly Targeted Agents ,
Lijie Fan ,
Chief Executive Officer ,
Accutar Biotechnology ,
Business Wire ,